 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Why the extremely high short position still? 4.1 million shares, over 40 days of average daily trading volume, of the 30 million shares o/s at least 20 million are closely held, of the float I am guessing 90% is in institutional hand. The company is a pure play in the fast growing vaccine industry 1) they have several patents on unique advanced technologies in the development of combinant and conjugate vaccaines 2) FDA approval for their first product , DTaP vaccine, is imminant 3) They have 17 vaccines at various stages of development in the pipeline. 4) Their list of sponsorships, partnerships, and alliances is very impressive. 5) They recently entered into an agreement with Abbott Labns to market their vaccines in th U.S. 6) Five members of their management team came from Merck. 7) The downside is that they be taken over by the likes of Abbott sometime in the future at a number that most would agree would exceed todays market cap given that their pipeline of products are addressing a market that would allow them to have revenues well in excess of one billion by the year 2000. So whats up? What am I missing? I would like some opinions. Shoot me down if need be. I am open for discussion and I recognize I am perhaps abit bias. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |